I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ATS 2021

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

May 27 / Roche and Genentech
Baseline Biomarker Levels Correlate With Degree of Fibrosis in Early ILD, Unclassifiable ILD, IPF, Advanced IPF, and Systemic Sclerosis Clinical Trial Cohorts
In an analysis comparing baseline levels of serum biomarkers across healthy controls, newly diagnosed IPF and non-IPF ILD, UILD, established IPF, advanced IPF and SSc patients, the level of lung damage or additional organ involvement appeared to contribute to overall circulating biomarker levels.

Sign up or login to unlock the full suite of MEDICALLY features

May 14 / Roche and Genentech
Listen to Dr. Khanna speak about Preservation of Lung Function With Tocilizumab in Patients With Systemic Sclerosis Interstitial Lung Disease: Analysis From the Double-Blind Period of a Phase 3 Trial
Post hoc analysis of patients from the double-blind period of the phase 3 randomized controlled focuSSced trial who had evidence of interstitial lung disease at baseline showed that early identification of interstitial lung disease and initiation of tocilizumab treatment may help preserve lung function in patients with systemic sclerosis-associated interstitial lung disease and elevated inflammatory markers.

Sign up or login to unlock the full suite of MEDICALLY features

May 14 / Roche and Genentech
Preservation of Lung Function With Tocilizumab in Patients With Systemic Sclerosis Interstitial Lung Disease: Analysis From the Double-Blind Period of a Phase 3 Trial
Post hoc analysis of patients from the double-blind period of the phase 3 randomized controlled focuSSced trial who had evidence of interstitial lung disease at baseline showed that early identification of interstitial lung disease and initiation of tocilizumab treatment may help preserve lung function in patients with systemic sclerosis-associated interstitial lung disease and elevated inflammatory markers.
10:10 AM
Duration 3mins Virtual
Tocilizumab in Systemic Sclerosis Interstitial Lung Disease: Safety and Efficacy in the Double-Blind and Open-Label Periods of a Randomized Controlled Phase 3 Trial
Dinesh Khanna, MD, Celia J. F. Lin, MD, Daniel E. Furst, MD, Mauro Zucchetto, MS, Ganesh Raghu, MD, Fernando J. Martinez, MD, Christopher P. Denton, FRCP

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar